| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Mrz―04 |
Psilocybin therapy might help frontline pandemic workers |
|
| 2 |
[GO] |
2024―Jun―04 |
Use of ADHD medications increased sharply during pandemic |
|
| 3 |
[GO] |
2024―Jun―04 |
More pandemic reverberations: Focus on stimulants |
Lawrence H. Price |
| 4 |
[GO] |
2023―Apr―03 |
Antipsychotic prescribing for dementia patients rose worldwide during pandemic |
|
| 5 |
[GO] |
2022―Dez―10 |
Expanded access to OUD medication during pandemic proved beneficial |
|
| 6 |
[GO] |
2022―Nov―03 |
Fluvoxamine and other drugs fail to prevent complications in COVID-19 patients |
|
| 7 |
[GO] |
2022―Jul―05 |
Among hospitalized, newer antipsychotics associated with reduced risk of COVID-19 |
|
| 8 |
[GO] |
2022―Feb―01 |
Study suggests use of SSRIs could reduce COVID-19 severity |
|
| 9 |
[GO] |
2022―Feb―01 |
No increased risk of death from COVID-19 with antipsychotic treatment |
|
| 10 |
[GO] |
2022―Feb―01 |
Psychopharmacology research: Pandemic reverberations |
Lawrence H. Price |
| 11 |
[GO] |
2022―Jan―03 |
Fluvoxamine lowers hospitalization risk in patients with COVID-19 |
|
| 12 |
[GO] |
2022―Jan―03 |
Prescribing trends during pandemic suggest impact of mitigation efforts |
|
| 13 |
[GO] |
2021―Jul―05 |
COVID-19 infection and psychotropics |
Y. W. Francis Lam |
| 14 |
[GO] |
2021―Jun―04 |
Nursing homes' prescribing of psychotropics higher in pandemic |
|
| 15 |
[GO] |
2021―Jun―04 |
The perils of pandemic psychopharmacology |
Lawrence H. Price |
| 16 |
[GO] |
2021―Mrz―05 |
Study suggests fluvoxamine may limit deterioration from COVID-19 |
|
| 17 |
[GO] |
2020―Aug―03 |
The COVID-19 commentary |
Lawrence H. Price |
